Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDF3 | Q7Z739 | 1/20 | 0.35 |
| ▸ | YTHDF1 | Q9BYJ9 | 1/20 | 0.35 |
| ▸ | YTHDF2 | Q9Y5A9 | 1/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.30 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21982937 | 0.73 | GRIN2D (0.42) | GRIA1CACNG8 | |
| SCHEMBL22169013 | 0.71 | KIF11 (0.40) | — | |
| SCHEMBL19677848 | 0.66 | CA2 (0.54) | — | |
| SCHEMBL22928150 | 0.66 | KIF11 (0.53) | GRIA1CACNG8 | |
| SCHEMBL13765834 | 0.65 | GRIA1 (0.33) | GRIA1CACNG8 | |
| SCHEMBL19677843 | 0.62 | CA2 (0.48) | — | |
| SCHEMBL24007751 | 0.62 | BRD4 (0.33) | YTHDF2 | |
| SCHEMBL6193229 | 0.61 | SMYD3 (0.43) | YTHDF3YTHDF1YTHDF2GRIA1CACNG8 | |
| SCHEMBL802736 | 0.61 | ESR2 (0.48) | — | |
| SCHEMBL23220291 | 0.61 | ALDH1A1 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647703-B2 | Inhibitors of KRAS G12C mutant proteins | ARAXES PHARMA LLC (US) | 2020-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647703-B2 | Inhibitors of KRAS G12C mutant proteins | KRAS, NRAS, G3BP1 | YTHDF3 4016/4885YTHDF1 3539/4885YTHDF2 4147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.